BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xia J, Huang R, Chen Y, Liu Y, Wang J, Yan X, Zhang Z, Wu C. Profiles of serum soluble programmed death-1 and programmed death-ligand 1 Levels in chronic hepatitis B virus-infected patients with different disease phases and after anti-viral treatment. Aliment Pharmacol Ther. 2020;51:1180-1187. [PMID: 32363582 DOI: 10.1111/apt.15732] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H, Chen H, Han Y, Yang Y, Xu X. High levels of soluble programmed death-1 are associated with virological response in chronic hepatitis B patients after antiviral treatment. Virus Res 2021;309:198660. [PMID: 34929214 DOI: 10.1016/j.virusres.2021.198660] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Chu YJ, Jeng WJ, Pan MH, Hu HH, Luo WS, Su CY, Chiang CT, Jen CL, Chen CJ, Yang HI. Serum soluble programmed death-1 levels predict the spontaneous HBeAg seroclearance in chronic hepatitis B. J Gastroenterol 2022. [PMID: 35459967 DOI: 10.1007/s00535-022-01874-8] [Reference Citation Analysis]
3 Kozuka R, Enomoto M, Dong MP, Hai H, Thuy LTT, Odagiri N, Yoshida K, Kotani K, Motoyama H, Kawamura E, Hagihara A, Fujii H, Uchida-Kobayashi S, Tamori A, Kawada N. Soluble programmed cell death-1 predicts hepatocellular carcinoma development during nucleoside analogue treatment. Sci Rep 2022;12:105. [PMID: 34996935 DOI: 10.1038/s41598-021-03706-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kramvis A, Chang KM, Dandri M, Farci P, Glebe D, Hu J, Janssen HLA, Lau DTY, Penicaud C, Pollicino T, Testoni B, Van Bömmel F, Andrisani O, Beumont-Mauviel M, Block TM, Chan HLY, Cloherty GA, Delaney WE, Geretti AM, Gehring A, Jackson K, Lenz O, Maini MK, Miller V, Protzer U, Yang JC, Yuen MF, Zoulim F, Revill PA. A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35859026 DOI: 10.1038/s41575-022-00649-z] [Reference Citation Analysis]
5 Liao G, Liu Z, Xia M, Chen H, Wu H, Li B, Yu T, Cai S, Zhang X, Peng J. Soluble Programmed Cell Death-1 is a Novel Predictor of HBsAg Loss in Chronic Hepatitis B Patients When Long-Term Nucleos(t)ide Analog Treatment is Discontinued. IDR 2022;Volume 15:2347-57. [DOI: 10.2147/idr.s360202] [Reference Citation Analysis]
6 Zhang J, Chen L, Xu Q, Tao Y, Pan J, Guo J, Su J, Xie H, Chen Y. An automated, rapid fluorescent immunoassay to quantify serum soluble programmed death-1 (PD-1) protein using testing-on-a-probe biosensors. Clin Chem Lab Med 2022. [PMID: 35535427 DOI: 10.1515/cclm-2022-0166] [Reference Citation Analysis]
7 Tan N, Luo H, Kang Q, Pan JL, Cheng R, Xi HL, Chen HY, Han YF, yang YP, Xu XY. Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment. World J Clin Cases 2021; 9(21): 5812-5821 [PMID: 34368300 DOI: 10.12998/wjcc.v9.i21.5812] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Xuan Hoan N, Thi Minh Huyen P, Dinh Tung B, Phuong Giang D, Tat Trung N, Tien Sy B, Thi Tuan N, Thi Ngoc Dung D, Reddy Pallerla S, Velavan TP, Hong Bang M, Huu Song L. Association of PD-L1 gene polymorphisms and circulating sPD-L1 levels with HBV infection susceptibility and related liver disease progression. Gene 2022;806:145935. [PMID: 34478821 DOI: 10.1016/j.gene.2021.145935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Huang R, Xia J, Wang J, Chen Y, Wu C. Letter: programmed death-1-a predictor for antiviral treatment in chronic hepatitis B. Authors' reply. Aliment Pharmacol Ther 2020;52:749-50. [PMID: 32886394 DOI: 10.1111/apt.15924] [Reference Citation Analysis]
10 Vyas AK. Letter: programmed death-1-a predictor for anti-viral treatment in chronic hepatitis B. Aliment Pharmacol Ther 2020;52:748. [PMID: 32886375 DOI: 10.1111/apt.15878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]